Financial Ratios NovoCure Limited
Equities
NVCR
JE00BYSS4X48
Medical Equipment, Supplies & Distribution
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
26.57 USD | -1.45% | +0.42% | -11.21% |
Dec. 02 | HC Wainwright Adjusts NovoCure Price Target to $38 From $30, Maintains Buy Rating | MT |
Dec. 02 | NovoCure's Shares Rise as Pancreatic Cancer Trial Meets Primary Endpoint | MT |
Fiscal Period: December | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||||
Return on Assets | -0.09 | 2.51 | -2.49 | -4.77 | -12.09 | |||||
Return on Total Capital | -0.11 | 2.94 | -2.85 | -5.51 | -14.19 | |||||
Return On Equity % | -4.38 | 5.71 | -13.16 | -21.73 | -51.52 | |||||
Return on Common Equity | -4.38 | 5.71 | -13.16 | -21.73 | -51.52 | |||||
Margin Analysis | ||||||||||
Gross Profit Margin % | 74.87 | 78.54 | 78.65 | 78.76 | 74.96 | |||||
SG&A Margin | 52.55 | 45.6 | 49.19 | 56.97 | 75.97 | |||||
EBITDA Margin % | 1.76 | 7.8 | -6.45 | -14.75 | -42.5 | |||||
EBITA Margin % | -0.17 | 6.23 | -8.17 | -16.53 | -44.4 | |||||
EBIT Margin % | -0.17 | 6.23 | -8.17 | -16.53 | -44.4 | |||||
Income From Continuing Operations Margin % | -2.06 | 4.01 | -10.91 | -17.2 | -40.65 | |||||
Net Income Margin % | -2.06 | 4.01 | -10.91 | -17.2 | -40.65 | |||||
Net Avail. For Common Margin % | -2.06 | 4.01 | -10.91 | -17.2 | -40.65 | |||||
Normalized Net Income Margin | -1.93 | 2.17 | -6.04 | -10 | -25.94 | |||||
Levered Free Cash Flow Margin | 5.77 | 12.23 | 18.36 | 8.54 | -2 | |||||
Unlevered Free Cash Flow Margin | 8.19 | 13.55 | 18.13 | 8.32 | -2.25 | |||||
Asset Turnover | ||||||||||
Asset Turnover | 0.86 | 0.65 | 0.49 | 0.46 | 0.44 | |||||
Fixed Assets Turnover | 14.06 | 12.97 | 11.2 | 8.76 | 6.11 | |||||
Receivables Turnover (Average Receivables) | 7.37 | 6.36 | 5.62 | 5.98 | 6.91 | |||||
Inventory Turnover (Average Inventory) | 3.82 | 4.15 | 4.41 | 4.25 | 3.78 | |||||
Short Term Liquidity | ||||||||||
Current Ratio | 5.1 | 8.8 | 7.53 | 7 | 5.78 | |||||
Quick Ratio | 4.71 | 8.38 | 7.29 | 6.73 | 5.46 | |||||
Operating Cash Flow to Current Liabilities | 0.31 | 0.87 | 0.58 | 0.19 | -0.41 | |||||
Days Sales Outstanding (Average Receivables) | 49.55 | 57.58 | 64.9 | 61.02 | 52.84 | |||||
Days Outstanding Inventory (Average Inventory) | 95.63 | 88.18 | 82.83 | 85.94 | 96.63 | |||||
Average Days Payable Outstanding | 129.86 | 150.94 | 207.11 | 241.58 | 240.44 | |||||
Cash Conversion Cycle (Average Days) | 15.31 | -5.17 | -59.38 | -94.63 | -90.97 | |||||
Long Term Solvency | ||||||||||
Total Debt/Equity | 77.26 | 94.58 | 141.76 | 133.77 | 166.75 | |||||
Total Debt / Total Capital | 43.59 | 48.61 | 58.64 | 57.22 | 62.51 | |||||
LT Debt/Equity | 75.13 | 93.22 | 140.13 | 132.45 | 164.48 | |||||
Long-Term Debt / Total Capital | 42.39 | 47.91 | 57.96 | 56.66 | 61.66 | |||||
Total Liabilities / Total Assets | 54.57 | 54.7 | 63.98 | 62.98 | 68.37 | |||||
EBIT / Interest Expense | -0.04 | 1.74 | -12.7 | -26.67 | -68.14 | |||||
EBITDA / Interest Expense | 0.78 | 2.52 | -7.9 | -21.67 | -62.75 | |||||
(EBITDA - Capex) / Interest Expense | 0.02 | 1.67 | -14.93 | -28.07 | -70.91 | |||||
Total Debt / EBITDA | 15.58 | 10.13 | -21.41 | -8.17 | -2.9 | |||||
Net Debt / EBITDA | -14.62 | -8.8 | 13.09 | 5.25 | 1.47 | |||||
Total Debt / (EBITDA - Capex) | 537.59 | 15.26 | -11.33 | -6.31 | -2.57 | |||||
Net Debt / (EBITDA - Capex) | -504.23 | -13.26 | 6.93 | 4.05 | 1.3 | |||||
Growth Over Prior Year | ||||||||||
Total Revenues, 1 Yr. Growth % | 41.62 | 40.72 | 8.23 | 0.52 | -5.3 | |||||
Gross Profit, 1 Yr. Growth % | 56.23 | 47.61 | 8.38 | 0.66 | -9.86 | |||||
EBITDA, 1 Yr. Growth % | -123.99 | 522.87 | -189.54 | 129.8 | 172.81 | |||||
EBITA, 1 Yr. Growth % | -98.24 | -5.35K | -241.82 | 103.49 | 154.36 | |||||
EBIT, 1 Yr. Growth % | -98.24 | -5.35K | -241.82 | 103.49 | 154.36 | |||||
Earnings From Cont. Operations, 1 Yr. Growth % | -88.62 | -373.97 | -394.58 | 58.58 | 123.75 | |||||
Net Income, 1 Yr. Growth % | -88.62 | -373.97 | -394.58 | 58.58 | 123.75 | |||||
Normalized Net Income, 1 Yr. Growth % | -77.24 | -258.8 | -400.91 | 66.33 | 145.66 | |||||
Diluted EPS Before Extra, 1 Yr. Growth % |